To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

NCT04853342 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

318

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Carcinoma

Interventions

DRUG: Drug: Furmonertinib 80 mg
DRUG: Furmonertinib 80 mg placebo

Sponsor

Allist Pharmaceuticals, Inc.